Improving patient access and retention in clinical trials for CROs and pharma

Improving patient access and retention in clinical trials for CROs and pharma  

14th April 2016, London, UK

ICC London have announced the official launch of their patient access and retention department (PAR), which specialises in assisting pharmaceutical companies and CROs with recruiting and retaining patients for clinical trials.  

Over 25,000 trails are published every year - but only 55% meet patient recruitment targets.  

By utilising the increasingly connected world in which patients now live, ICC have been creating prototype tools that help with the costly and time-consuming issue of patient access and recruitment.  

Over the past year, ICC have already trialled this offering with CROs - to great success. Their services have helped hit patient trial quotas, months before target deadline.  

Now, these pioneering digital solutions are available to all their clients to help improve target numbers in a cost-effective way.  

Otis Baker, MD at ICC HC, commented: “We are excited to have built an innovative in-house team and a truly unique offering. By making the most of today’s digital landscape, we look forward to helping CRO and pharma companies with their clinical trial recruitment.”  

For more information about our PAR services please contact otis.baker@icc-hc.com      

www.icc-hc.com @icchclondon